What's breaking now, across thousands of outlets.
Survival rates for childhood cancer now exceed 80%—but this also means more children are living with the long-term emotional and psychosocial impacts of cancer.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
A Medicare coverage fight over DCIS biomarker testing raises a critical question: Who decides when the evidence is strong enough to guide radiation treatment?
Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
With 14 risk factors we can target. Don't miss a story, subscribe here.
BCB-276 is designed to treat diffuse intrinsic pontine glioma (DIPG) by targeting B7-H3, an immune checkpoint protein encoded by the CD276 gene that has been shown to be involved in tumor progression…
Two companies that have spent decades trying to develop cell therapies for diabetes are set to merge, with the aim of working together to take on a market also being pursued by Vertex and CRISPR ...
[Capital FM] Nairobi -- More than half of Kenyans living with metabolic disease do not know they have the disease, while the national caseload is expected to double by 2050, a gap clinicians meeting…
